WestEnd Advisors LLC Buys 8,528 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• WestEnd Advisors increased its Regeneron position by 43.9% in the third quarter, buying 8,528 shares for a total holding of 27,947 shares valued at approximately $21.2 million. Institutional investors collectively own 83.31% of the company.
• Regeneron has several potential growth catalysts, including a $270 million BARDA extension for its Inmazeb Ebola treatment, promising demand for partner Kiniksa’s Arcalyst, and durable survival data for Libtayo.
• Wall Street maintains a “Moderate Buy” consensus with an average price target of $846.28, while REGN shares recently opened at $816.10. Investors are also watching upcoming earnings and the impact of Regeneron recording its full share of Dupixent profits.

WestEnd Advisors LLC lifted its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 43.9% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 27,947 shares of the biopharmaceutical company's stock after purchasing an additional 8,528 shares during the quarter. WestEnd Advisors LLC's holdings in Regeneron Pharmaceuticals were worth $21,194,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Western Wealth Management LLC acquired a new stake in Regeneron Pharmaceuticals during the first quarter valued at $26,000. Armstrong Advisory Group Inc. raised its position in shares of Regeneron Pharmaceuticals by 466.7% in the third quarter. Armstrong Advisory Group Inc. now owns 34 shares of the biopharmaceutical company's stock worth $26,000 after acquiring an additional 28 shares during the period. Mowery & Schoenfeld Wealth Management LLC acquired a new position in shares of Regeneron Pharmaceuticals in the second quarter worth about $29,000. Trust Co. of Vermont purchased a new stake in shares of Regeneron Pharmaceuticals during the 2nd quarter worth about $29,000. Finally, Fiduciary Financial Advisors purchased a new stake in shares of Regeneron Pharmaceuticals during the 2nd quarter worth about $29,000. 83.31% of the stock is owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals News Roundup

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Regeneron extended its agreement with the U.S. Biomedical Advanced Research and Development Authority (BARDA) to supply additional doses of Inmazeb, its Ebola treatment. The extension adds approximately $270 million in value and supports near-term revenue visibility. Regeneron Extends Agreement with BARDA to Provide Additional Supply of Ebola Treatment Inmazeb for U.S. Preparedness
• Positive Sentiment: Strong third-quarter results from partner Kiniksa highlighted growing demand and blockbuster potential for Arcalyst, which is partnered with Regeneron. The update may reinforce expectations for increased royalty or collaboration-related contributions. Kiniksa jumps as Q3 results show blockbuster prospects for Regeneron-partnered Arcalyst
• Positive Sentiment: Regeneron released nearly four years of survival-benefit data for Libtayo, its cancer immunotherapy. Durable efficacy could support the drug’s commercial positioning and future adoption. Regeneron Pharmaceuticals Posts Nearly Four Years of Survival Benefit Data for Libtayo
• Neutral Sentiment: Analysts expect third-quarter earnings of approximately $16.19 per share, with results due October 30. Investors are also focused on Regeneron recording its full share of Dupixent profits with Sanofi for the first time, a potentially significant earnings catalyst but one already receiving attention ahead of the report. Regeneron Q3 earnings preview
• Neutral Sentiment: Recent commentary describes REGN as an increasingly diversified investment and a strong value stock. Reported short interest of zero shares provides no meaningful bearish signal, although the figure may reflect a data-reporting issue rather than actual market positioning. Has Regeneron Stock Become a Different Bet?

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on the company. Guggenheim raised their target price on Regeneron Pharmaceuticals from $1,000.00 to $1,030.00 and gave the company a "buy" rating in a research report on Monday, August 3rd. Truist Financial upped their price target on Regeneron Pharmaceuticals from $772.00 to $780.00 and gave the stock a "buy" rating in a report on Wednesday, October 7th. Sanford C. Bernstein upped their price target on Regeneron Pharmaceuticals from $753.00 to $756.00 and gave the stock a "market perform" rating in a report on Friday, August 14th. The Goldman Sachs Group increased their price target on Regeneron Pharmaceuticals from $965.00 to $972.00 and gave the stock a "buy" rating in a research report on Friday, July 31st. Finally, UBS Group raised Regeneron Pharmaceuticals from a "neutral" rating to a "buy" rating and raised their price objective for the company from $660.00 to $978.00 in a report on Thursday, October 15th. One analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and eight have issued a Hold rating to the stock. According to MarketBeat.com, Regeneron Pharmaceuticals has an average rating of "Moderate Buy" and a consensus target price of $846.28.

Regeneron Pharmaceuticals Stock Up 1.0%

Shares of NASDAQ REGN opened at $816.10 on Wednesday. The firm has a 50-day simple moving average of $791.66 and a 200-day simple moving average of $737.08. The stock has a market capitalization of $84.02 billion, a price-to-earnings ratio of 20.17 and a beta of 0.16. Regeneron Pharmaceuticals, Inc. has a 52 week low of $591.52 and a 52 week high of $859.34.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share for the quarter, topping analysts' consensus estimates of $10.16 by $4.13. The business had revenue of $4.29 billion for the quarter, compared to analyst estimates of $3.82 billion. During the same quarter in the previous year, the firm posted $12.81 earnings per share. The business's revenue was up 16.7% compared to the same quarter last year. As a group, equities research analysts expect that Regeneron Pharmaceuticals, Inc. will post 49.10 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Monday, August 31st. Shareholders of record on Tuesday, August 18th were paid a $0.94 dividend. This represents a $3.76 dividend on an annualized basis and a yield of 0.5%. The ex-dividend date of this dividend was Tuesday, August 18th. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is 9.29%.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other news, Director Huda Y. Zoghbi sold 800 shares of the company's stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $800.00, for a total value of $640,000.00. Following the completion of the sale, the director directly owned 1,703 shares in the company, valued at $1,362,400. This represents a 31.96% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Marion Mccourt sold 1,215 shares of the stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $850.00, for a total value of $1,032,750.00. Following the completion of the sale, the executive vice president directly owned 13,134 shares of the company's stock, valued at approximately $11,163,900. This represents a 8.47% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 8,093 shares of company stock valued at $6,506,845. Company insiders own 6.97% of the company's stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses genetic and antibody-based research technologies to develop treatments in areas including eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease, infectious diseases and rare disorders.

Its marketed products include Eylea and Eylea HD for retinal diseases, Dupixent for several inflammatory and allergic conditions, Libtayo for certain cancers, Praluent for cardiovascular disease, Kevzara for rheumatoid arthritis, and other medicines such as Inmazeb, Evkeeza, Veopoz and Arcalyst.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.